Browse Studies — Arctuva

Phase 2

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the lab…

Metastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Ovarian Cancer+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT01174121

Phase 2

A Phase 2 Non-comparative Screening Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy

This is a phase II, two-arm, noncomparative screening study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, admin…

Ovarian Clear Cell CarcinomaMetastatic Ovarian CancerRecurrent Ovarian Clear Cell Adenocarcinoma

Estimated

~$10 – $6,250

Tufts Medical CenterNCT07718854

Phase 1

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.

This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian o…

Ovarian CancerEndometrial CancerPlatinum-resistant Ovarian Cancer (PROC)+2 more

Estimated

~$10 – $8,750

ArriVent BioPharma, Inc.NCT07755436